FORM 6-K
 

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 


For period ending May 2010
 

GlaxoSmithKline plc
(Name of registrant)
 
 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 

Form 20-F x Form 40-F
 

 --

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
Yes No x
  --

GlaxoSmithKline plc - Result of AGM
 
GlaxoSmithKline (GSK) announces that at its Annual General Meeting today, all resolutions, including those electing and re-electing Board members, were passed by shareholders.
 
GlaxoSmithKline Annual General Meeting Poll Results
 
The following table shows the votes cast for each resolution:
 
Resolution
Total votes for*
%
Total votes against
%
Total votes cast
Votes withheld**
1
Adoption of Financial Statements
3,598,418,923
98.82
43,141,670
1.18
3,641,560,593
5,644,370
2
Approval of the Remuneration Report
3,541,237,234
97.79
79,954,611
2.21
3,621,191,845
26,063,218
3
Re - Election of Dr Stephanie Burns
3,623,167,103
99.42
21,029,709
0.58
3,644,196,812
2,994,975
4
Re-election of Julian Heslop
3,614,453,830
99.40
21,794,823
0.60
3,636,248,653
10,945,821
5
Re-election of Sir Deryck Maughan
3,610,735,860
99.09
33,299,858
0.91
3,644,035,718
3,157,277
6
Re-election of Dr Daniel Podolsky
3,611,533,790
99.11
32,510,583
0.89
3,644,044,373
3,147,398
7
Re-election of Sir Robert Wilson
3,610,344,137
99.08
33,643,265
0.92
3,643,987,402
3,191,304
8
Re-appointment of Auditors
3,478,245,182
96.93
110,136,263
3.07
3,588,381,445
58,819,622
9
Remuneration of Auditors
3,564,492,662
98.45
56,106,748
1.55
3,620,599,410
26,616,714
10
To authorise the company to make donations to Political Organisations & incur Political Expenditure
3,542,930,783
97.36
95,902,968
2.64
3,638,833,751
8,442,409
11
Authority to allot shares
3,522,619,757
96.76
118,105,636
3.24
3,640,725,393
6,450,059
12
Disapplication of pre-emption rights***
3,605,918,864
99.14
31,425,913
0.86
3,637,344,777
9,718,766
13
Authority for the Company to purchase its own shares***
3,589,455,513
98.56
52,518,615
1.44
3,641,974,128
5,301,338
14
Exemption from statement of senior statutory auditor's name
3,624,009,356
99.65
12,682,719
0.35
3,636,692,075
10,468,603
15
Reduced notice of a general meeting other than an AGM***
3,367,402,408
92.71
264,960,544
7.29
3,632,362,952
14,848,460
16
Adoption of new Articles of Association***
3,576,628,823
99.44
20,021,827
0.56
3,596,650,650
50,514,919
 
Notes:
*           Includes discretionary votes.
**         A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.
***        Indicates Special Resolutions requiring a 75% majority
 
The following table provides further relevant information:
 

 
GlaxoSmithKline's
Tenth AGM
(2010)
 
 
GlaxoSmithKline's
Ninth AGM
(2009)
 
Issued share capital
(excluding Treasury Shares)
5,192,489,588
5,188,385,638
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)
70.24%
73.50%
Total shareholder population
164,450
170,054
Total number of proxies lodged
11,148
10,580
% of shareholders who lodged proxies
6.78%
6.22%
Number of shareholders,  corporate representatives and proxies who attended the AGM
325
276
 
S M Bicknell
Company Secretary
6 May 2010
 
These results will shortly be available on the Company's website
www.gsk.com
.
 
Enquiries:
 
GlaxoSmithKline Enquiries:


UK Media enquiries:
Philip Thomson
(020) 8047 5502

Claire Brough
(020) 8047 5502

Stephen Rea
(020) 8047 5502

Alexandra Harrison
(020) 8047 5502

Jo Revill
(020) 8047 5502



US Media enquiries:
Nancy Pekarek
(919) 483 2839

Mary Anne Rhyne
(919) 483 2839

Kevin Colgan
(919) 483 2839

Sarah Alspach
(919) 483 2839



European Analyst/Investor enquiries:
David Mawdsley
(020) 8047 5564

Sally Ferguson
(020) 8047 5543

Gary Davies
(020) 8047 5503



US Analyst/ Investor enquiries:
Tom Curry
(215) 751 5419

Jen Hill Baxter
(215) 751 7002
 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 

GlaxoSmithKline plc
(Registrant)
 
 

Date: May 06, 2010

By: VICTORIA WHYTE

------------------

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc